Striving towards disease-free skin
A/Prof. Pablo Fernandez-Peñas was invited to the 40th Annual Dermatology Conference of the Persatuan Dermatologi Malaysia to talk about “Quality of Life and Patient-Reported Outcomes in Psoriasis”. Patients with psoriasis have to deal with the challenge of rejection and life impairment, and this can be measured using different Patient Reported Outcomes (PRO). Generic instruments that …
A/Prof Pablo Fernandez-Peñas was invited to attend the 7th Annual Meeting of the Asian Society for Pigment Cell Researchin Shanghai (China). He reviewed our papers on the Cutaneous Side Effects of BRAF inhibitors, MEK inhibitors, anti-CTLA4 and anti-PD1 therapies (Publications) and new results not yet published. Although melanoma is not as a big issue in most …
Ali Azimi, PhD student from our department has been on the organising committee for 2015 Cancer Life-span Symposium. Congratulations Ali for the great work! ***************** The 2015 Cancer Life-span Symposium was held on 9th of September at the Westmead Millennium Institute and more than 90 cancer researchers had attended the symposium. The symposium which was …
A/Prof Pablo Fernandez-Peñas was interviewed regarding sun protection and winter months. This interview appeared in the Manly Daily newspaper. The message is clear: “We can’t feel UV light, and the heat sensation is not related to the amount of UV light”. If you want to read the rest of the interview, you should be able …
Westmead Hospital week research symposium is on from 19th of August until 21st of August 2015. Dermatology has 5 posters (Poster numbers 18-22) on display covering recent topics in melanoma therapy including BRAF inhibitors and targeted immunotherapies. We are also presenting the exciting first set of data on proteomics analysis of squamous cell carcinoma, one …
Our paper in JAMA Dermatology has triggered interviews in Medscape and Reuters Health. This is a nice and welcome surprise for our team.
We have reviewed, in our population of patients with metastatic melanoma on targeted therapies, the cutaneous side effects of BRAF single agent (Dabrafenib or Vemurafenib) and the combination therapy (Dabrafenib + Trametinib). There are minimal differences between Dabrafenib and Vemurafenib (being photosensitivity the most important), but there are very significant differences between Dabrafenib and the …
A/Prof. Pablo Fernandez-Peñas has just arrived from Hsinchu (Taiwan) and Hong Kong. He was invited to talk about psoriasis, and, in particular, why we have to treat more than the skin, in two IMID (Immune Mediated Inflammatory Diseases) meetings. Gastroenterologists, Rheumatologists and Dermatologists from East Asia attended these meetings sponsored by Abvvie. Pablo reviewed the …
Often, it is very challenging to analyze and interpret the large data generated by techniques such as microarray and mass spectrometry. To overcome this issue, there have been few bioinformatics tools such as Ingenuity Pathway Analysis (IPA) developed that use the information already available in the literature to map the set of experimental data to …
First year Dermatology registrar Dr Burcu Kim has recently received 2 awards for her research, conducted at the Skin Hospital (Skin & Cancer Foundation Australia) with A/Prof Pablo Fernández-Peñas, titled ‘Scar outcomes in Dermatologic Surgery’. The Eileen Collins Memorial Prize, sponsored by the NSW faculty, and the Best Paper in the Registrars Forum at the …